Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5576002 | 0.88 | CXCR4 (0.37) | CYP2A6MEN1KMT2AADORA2ACHRM2 | |
| SCHEMBL2084845 | 0.78 | TMEM97 (0.38) | CYP2A6CHRM2MAPK1CXCR4 | |
| SCHEMBL2084170 | 0.77 | CXCR4 (0.41) | CYP2A6CHRM2CXCR4 | |
| SCHEMBL11935014 | 0.77 | CHRM2 (0.45) | ADORA2ACHRM2CYP1A2CXCR4ADORA1 | |
| SCHEMBL2080968 | 0.75 | CXCR4 (0.39) | CYP2A6MEN1KMT2AADORA2ACHRM2 | |
| SCHEMBL2311388 | 0.75 | PLAU (0.48) | CYP2A6MEN1KMT2AADORA2AMAPK1 | |
| SCHEMBL23398172 | 0.74 | CXCR4 (0.42) | MEN1KMT2AADORA2ACHRM2SLC40A1 | |
| SCHEMBL2084248 | 0.74 | TP53 (0.38) | KMT2AADORA2ACHRM2MAPK1SLC40A1 | |
| SCHEMBL30482129 | 0.72 | CYP2A6 (0.47) | CYP2A6MEN1KMT2AADORA2AMAPK1 | |
| SCHEMBL7334545 | 0.72 | CYP2A6 (0.47) | CYP2A6MEN1KMT2AADORA2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | ANORMED CORPORATION (CA) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | CXCR4, CXCR1, CXCR3 | CYP2A6 3010/4885MEN1 4472/4885KMT2A 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.